Navigation Links
Hemispherx Presents Potential Avian Influenza Treatment,Breakthrough at Paris Conference

PARIS--(BUSINESS WIRE)--May 31, 2007 - Hemispherx Biopharma, Inc. (AMEX: HEB), a biopharmaceutical company engaged in the clinical development and manufacture of new drug entities for pandemic disease threats, announced today a new scientific report featuring its antiviral therapeutic product candidate Alferon-LDO in combating highly pathogenic avian influenza (HPAI), also known as "bird flu." Alferon-LDO is a low-dose experimental oral formulation of the Company's Alferon-N(TM) product, which is already approved by the United States FDA for the treatment of refractory genital warts (HPV).

The report concludes that Alferon-LDO appears to have potential as a preventive agent and/or treatment against avian influenza, reducing the severity of pathology resulting from infection of established animal model non-human primates (macaques) by a highly pathogenic strain of avian flu.

As noted in a 2006 Oxford University Clinical Research Unit study titled "Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia," illness caused by the avian influenza A virus stems most directly from the body's own response to infection, an overwhelming reaction sometimes termed a "cytokine storm." In the words of the Oxford University study, "high viral load, and the resulting intense inflammatory responses, are central to influenza H5N1 pathogenesis. The focus of clinical management should be on preventing this intense cytokine response, by early diagnosis and effective antiviral treatment."

To study the effects of Alferon-LDO, researchers administered macaque subjects with the drug via the animals' gum tissues, in a range of three dosing concentrations, with a fourth untreated group serving as a control. Following exposure of the dosed and untreated test subjects to the highly pathogenic HPAI strain A/Vietnam/1194/04, throat and nasal swabs were taken, gross pathology and viral lo
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Hemispherx Presents Evidence of Ampligen Synergies with Existing Antivirals at International Avian Influenza Conference
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
(Date:1/23/2015)... Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) ... of Advaxis, Inc. ("Advaxis" or the "Company") (NASDAQ: ... its fiduciary duties to shareholders. On January ... website reporting that Advaxis had misrepresented the clinical data ...
(Date:1/23/2015)... 23, 2015  iMD Companies, Inc. (ICBU) has repositioned itself as ... and grab a foothold in the hydroponic, hemp and medical ... a presence in the sector, and recently partnering with the ... hemp and medical marijuana, iMD is committing to bring its ...
(Date:1/23/2015)... 2015  CytoSorbents Corporation (NASDAQ CM: CTSO), a critical ... adsorber to reduce deadly inflammation in critically-ill and ... net of transaction costs, in non-dilutive funding as ... Certificate Transfer Program sponsored by the New Jersey ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3
... Roper Industries, Inc.   (NYSE: ... 2009, ended December 31, 2009 , will be released before the ... to discuss these results has been scheduled for 8:30 AM ET ... accessed via webcast or by dialing +1 888-539-3679 (US/ Canada ) or ...
... SAN DIEGO , Jan. 20 First Coast ... to treat breast cancer with the addition of a Naviscan PEM ... in the nation to use both a PEM scanner and the ... , AccuBoost is a technique for whole breast irradiation that is ...
Cached Medicine Technology:First Coast Oncology Deploying Both Naviscan(TM) PEM and AccuBoost(TM) Assisted Therapy to Optimize Breast Cancer Treatment 2First Coast Oncology Deploying Both Naviscan(TM) PEM and AccuBoost(TM) Assisted Therapy to Optimize Breast Cancer Treatment 3
(Date:1/23/2015)... January 23, 2015 Hastings and Hastings, a ... reports a record number of legal representation client review requests ... has been a steady rise in the number of slip ... at home throughout the Valley. With that said, a large ... reviewed by an experienced law firm. Hastings and Hastings is ...
(Date:1/22/2015)... 2015 The City of West Hollywood hosted a ... commemorate the 42nd anniversary of the Supreme Court decision Roe v. ... 42 years since the Roe vs. Wade decision and the fight ... as ever,” said City of West Hollywood Councilmember Abbe Land. “We ...
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method put together ... by up to 30lbs in less than 12 weeks without ... Stevenson, prompting an investigative review. , “Our Incredible Bulk ... formula that allows the body to pack on a massive ...
(Date:1/22/2015)... 2015 Juvent Sports ( http://www.juventsports.com ) ... PGA Merchandise Show to bestow a Juvent Sports Achievement ... golfer, Arlene McKitrick. The award commemorated and congratulated McKitrick ... win. She won her first amateur tournament in 1979 ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post presenting the basic ... , Purchasing an accidental death and dismemberment rider for a ... rider provides benefits if the insured dies in an accident. ... of life insurance. , AD&D is not expensive and ...
Breaking Medicine News(10 mins):Health News:Hastings and Hastings Reports a Record Number of Client Review Requests for Slip and Fall Accidents in 2014 2Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2
... According to a new research, a daily dose of a ... the "bad", or LDL, cholesterol levels in young men. Functional ... supplying essential nutrients. //There has been a trend of adding ... healthier. For example, Benecol Spread is a margarine that contains ...
... University of Hopkins found a new study shows some ... may benefit from treatment with the drug, interferon.,Past research ... and some B-cell non-Hodgkin's lymphoma's. //A patient with both ... interferon. The patient responded causing researchers in Paris to ...
... valve problems are generally advised to take antibiotics before ... But many who need the drugs do not take ... them and may not even realize that the antibiotics ... put forward a simple suggestion that they say may ...
... should keep their patients informed about being paid to ... 4 clinical trials - are a signicnificant part of medical ... family doctor reporting any problems that might arise. The post-marketing ... take part in previous trials and can be an important ...
... the body in stressful situations may help the immune ... report. According to a report in the June issue ... are special proteins produced by the body help cells ... the body. ,In the study Dr. Graham R. ...
... a leaky heart valve raises the risk of abnormal heart ... heart beat randomly and unsuccessfully. The condition is linked to ... have now shown that having a leaky heart valve - ... to AF. ,Blood flows backwards into the upper ...
Cached Medicine News:
... on the Alpha 5 include a newly ... digital processor specifically designed for ultrasonic signals. ... reduces image speckle and enables clearer imaging ... The enhanced user confidence afforded by Alpha ...
... the launch of the NCP-2, ACS proudly ... has given physicians more tools for assessing ... first and only complete ECP Treatment Report.,The ... software program that allows both physicians and ...
... Sun 100 monitors and controls patient temperature ... associated with surgery, trauma, or other medical ... to feedback provided from a patient temperature ... (room air) and 42C (107.6F) to achieve ...
The Androscope i-stethos is the next revolution in electronic auscultation. Plus, the ability to filter out ambient sounds, so healthcare professionals even those in noisy places like the ER could ...
Medicine Products: